HeRO Graft Clinical Data
Understand the clinical data and outcomes as Dr. Jeffrey H. Lawson and Shawn M. Gage, PA–C discuss the published data on HeRO Graft.

Fewer infections

  • 69% reduced infection rate compared with catheters1

Superior Dialysis Adequacy

  • 1.7Kt/V, a 16% to 32% improvement compared with catheters1

High Patency Rates

  • Up to 87% cumulative patency at 2 years1,2

Cost Savings

  • A 23% average savings per year compared with catheters3

Clinical Outcomes

HERO GRAFT
GAGE, ET AL. EJVES2
HERO GRAFT
KATZMAN, ET AL. JVS1
CATHETER LITERATURE1AV GRAFT LITERATURE1
Bacteremia Rates
(Infections/1,000 days)
0.140.702.30.11
Adequacy of Dialysis
(mean Kt/V) §
N/A1.71.29-1.461.37-1.62
Cumulative Patency
(at 1 year)
91%72%ǂ37%65%
Intervention Rate
(per year)
1.52.55.81.6-2.4

§ Note: Every 0.1 decrease in Kt/V increases the mortality rate by 7%4 and is significantly (P<0.05) associated with 11% more hospitalizations, 12% more hospital days, and a $940 increase in Medicare inpatient expenditures.5
ǂ 8.6 months

References

  1. Katzman, MD, et al., J Vasc Surg 2009.
  2. Gage et al., EJVES 2012.
  3. Dageforde et al., JSR 2012.
  4. Dhingra et al., Kidney Int 2001.
  5. 2006 NKF KDOQI, Guideline 4.